Aroa Biosurgery (ASX:ARX) Total Stockholders Equity: A$82.84 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ARX Aroa Biosurgery Ltd ASX:ARX
60 GF Score
Price A$0.61
GF Value A$0.77
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Aroa Biosurgery Total Stockholders Equity?

Aroa Biosurgery ASX:ARX -0.82% 60 Total Stockholders Equity is A$82.84 Mil as of Mar. 2026. GuruFocus rates ASX:ARX with a GF Score™ of 60/100 and a GF Value™ of A$0.77 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Aroa Biosurgery's Total Stockholders Equity for the quarter that ended in Mar. 2026 was A$82.84 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Aroa Biosurgery's Book Value per Share for the quarter that ended in Mar. 2026 was A$0.24. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Aroa Biosurgery's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.06.

Aroa Biosurgery  (ASX:ARX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Aroa Biosurgery's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(82.838-0)/345.476
=0.24

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Aroa Biosurgery's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.235 + 4.082) / 82.838
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery Total Stockholders Equity Related Terms

Aroa Biosurgery Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Aroa Biosurgery's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery Total Stockholders Equity Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Stockholders Equity
Get a 7-Day Free Trial 93.40 95.38 87.09 84.59 82.84

Aroa Biosurgery Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 87.09 84.55 84.59 80.95 82.84
ASX:ARX
60GF Score
Aroa Biosurgery Ltd ASX:ARX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of A$82.84 Mil mean?
Aroa Biosurgery (ASX:ARX) has a Total Stockholders Equity of A$82.84 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Aroa Biosurgery and its competitors.
Is Aroa Biosurgery's Total Stockholders Equity too high?
Aroa Biosurgery's current Total Stockholders Equity is A$82.84 Mil. Overall, Aroa Biosurgery has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Total Stockholders Equity compare to ABT and SYK?
Aroa Biosurgery's Total Stockholders Equity of A$82.84 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Aroa Biosurgery and its competitors. Aroa Biosurgery's current Total Stockholders Equity is A$82.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.77, compared to a current price of A$0.61 — trading 21.4% below its estimated fair value. The current Total Stockholders Equity is A$82.84 Mil. Aroa Biosurgery's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current Total Stockholders Equity is A$82.84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?

Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued. The current stock price of A$0.61 is trading 21.4% below its estimated GF Value™ of A$0.77. GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.

Key valuation signals for ASX:ARX:

  • Total Stockholders Equity: A$82.84 Mil
  • GF Value™: A$0.77 vs. price of A$0.61 (21.4% below fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aroa Biosurgery Business Description

Other Exchanges AROAF:USA
Address 64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
60GF Score

Get the complete analysis for ASX:ARX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.61
Price
A$0.77
GF Value